Search clinical trials for: MK0524

Total 110 results

Merck Sharp & Dohme LLC

Completed

MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)

Seasonal Allergies
Merck Sharp & Dohme LLC

Completed

MK0524B Bioequivalence Study (0524B-070)

Dyslipidemia
Vyne Therapeutics Inc.

Completed

Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)

Overactive Bladder | Urinary Incontinence
Vyne Therapeutics Inc.

Terminated

A Study of MK0594 in Patients With Alcohol Dependence (0594-020)

Alcohol Dependence
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)

Migraine
Merck Sharp & Dohme LLC

Terminated

The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)

Middle Cerebral Artery Stroke
Merck Sharp & Dohme LLC

Completed

A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor

Healthy
Merck Sharp & Dohme LLC

Completed

Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042)

Migraine
Merck Sharp & Dohme LLC

Completed

Bioequivalence of Two Tablet Forms of MK0974 (0974-045)

Migraine
Merck Sharp & Dohme LLC

Completed

A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)

Obesity
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Completed

Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)

Post-Menopausal Osteoporosis
Merck Sharp & Dohme LLC

Terminated

MK0354 Clinical Efficacy and Tolerability Study (0354-004)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Terminated

A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)

Osteoarthritis

United States, Chile, Colombia, Mexico, Poland
Merck Sharp & Dohme LLC

Terminated

MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)

Alzheimer's Disease
Merck Sharp & Dohme LLC

Terminated

A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)

Myelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Leukemia, Lymphoblastic, Acute, T-cell | Myelogenous Leukemia
Merck Sharp & Dohme LLC

Completed

Lipid Efficacy Study (0524B-022)(COMPLETED)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)

Advanced Breast Cancer | Other Solid Tumors
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Odanacatib (0822-059)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)

Schizophrenia | Paranoid Schizophrenia
Merck Sharp & Dohme LLC

Completed

MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

Paranoid Schizophrenia
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)

Osteoporosis
Merck Sharp & Dohme LLC

Withdrawn

A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Prostate Cancer
Merck Sharp & Dohme LLC

Completed

Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)

Alzheimer's Disease
Ark Biosciences Inc.

Terminated

A Study of AK0529 in Infants Hospitalized With RSV

Respiratory Syncytial Virus Infections

Australia
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd.

Completed

A Study of AK0529 in Chinese Infants Hospitalized With RSV (AIRFLO)

Respiratory Syncytial Virus Infections

China
Merck Sharp & Dohme LLC

Completed

MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)

Prostatic Neoplasms
H. Lundbeck A/S

Terminated

Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)

Primary Insomnia
Merck Sharp & Dohme LLC

Completed

A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

MK0524 Asthma POC Study (0524-008)(COMPLETED)

Asthma
Merck Sharp & Dohme LLC

Completed

Effect of MK0524A on Cholesterol Levels (0524A-048)

Hypercholesterolemia | Hyperlipidemia
Merck Sharp & Dohme LLC

Terminated

Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED) (ACHIEVE)

Hypercholesterolemia, Familial
Ark Biosciences Inc.

Completed

Safety, Tolerability and PK Study of AK0529 in Healthy Human

Respiratory Syncytial Virus Infections

Australia
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)

Urinary Tract Infection
Ark Biosciences Inc.

Completed

A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers

Healthy

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors

Sarcoma | Lymphoma | Kidney Cancer | Testicular Germ Cell Tumor | Breast Cancer | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma

United States
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)

HIV Infections | Acquired Immunodeficiency Syndrome
Shanghai Ark Biopharmaceutical Co., Ltd.
Ark Biosciences Pty Ltd.

Completed

Viral Inhibition in Children for Treatment of RSV (VICTOR)

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Australia, Hong Kong, Israel, Lebanon, Malaysia, Poland, Taiwan, Turkey
Merck Sharp & Dohme LLC

Completed

Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)

Obesity
Ark Biosciences Inc.

Completed

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

Healthy Subjects

United States
Ark Biosciences Inc.

Unknown

Anti-RSV Study in Chinese Patients (ASCENT) (ASCENT)

Respiratory Syncytial Virus Infections

China
Ark Biosciences Inc.

Completed

A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529

Healthy

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)

Urinary Tract Infection
Merck Sharp & Dohme LLC

Completed

A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)

Rosacea
Merck Sharp & Dohme LLC

Terminated

Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)

Diabetes Mellitus Type 2
Merck Sharp & Dohme LLC

Completed

To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)

Sepsis
Merck Sharp & Dohme LLC

Terminated

Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)

Urinary Tract Infections
Merck Sharp & Dohme LLC

Completed

To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)

Pneumonia | Urinary Tract Infection | Infection

3

Subscribe